Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany

被引：0
|
作者：
Campone, M. [1 ]
Frenel, J-S. [1 ]
Kiver, V. I. I. [2 ,3 ,4 ]
Woeckel, A. [5 ]
Kerscher, A. G. [6 ]
Krebs, M. [6 ]
Leal, C. S. [7 ]
Saglimbene, V. M. [8 ]
Trankov, N. [9 ]
Sadetsky, N. [10 ]
Sjekloca, N. [11 ]
Libert, O. [12 ]
Kaushik, A. G. [13 ]
Bocquet, F. [14 ]
机构：
[1] ICO Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, St Herblain, France
[2] Charite Univ Med Berlin, Breast Ctr, Dept Gynecol, Berlin, Germany
[3] Free Univ Berlin, Berlin, Germany
[4] Humboldt Univ, Berlin, Germany
[5] Univ Hosp Wurzburg, Dept Obstet & Gynecol, Wurzburg, Germany
[6] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[7] IQVIA, Epidemiol & Database Studies, Porto Salvo, Portugal
[8] IQVIA Italy, EMEA Real World Methods & Evidence Generat, Milan, Italy
[9] IQVIA, EMEA Real World Methods & Evidence Generat, Sofia, Bulgaria
[10] Gilead Sci Inc, RWE Oncol, Foster City, CA USA
[11] Gilead Sci Europe Ltd, Global Med Affairs, Stockley Pk, England
[12] Gilead Sci SAS, Med Affairs, Boulogne, France
[13] Gilead Sci Inc, Hlth Econ Outcomes Res, Foster City, CA USA
[14] Inst Cancerol Ouest, Data Factory & Analyt, St Herblain, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.322
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
374P
引用
收藏
页码：S375 / S376
页数：2
相关论文
共 50 条
  • [21] Analysis of real world patient compliance to everolimus-based therapy among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC).
    Princic, Nicole
    Brouillette, Matthew
    Tang, Derek
    Lin, Chinjune
    Lanoue, Brad
    Barghout, Victoria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Patients' preferences for postmenopausal hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer treatments in Japan
    Omori, Y.
    Enatsu, S.
    Cai, Z.
    Ishiguro, H.
    CANCER RESEARCH, 2019, 79 (04)
  • [23] Real-world clinical outcomes in patients receiving cyclin-dependent kinase 4/6 inhibitors (iCDK 4/6) for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer in Mexico.
    Rodriguez, Benigno
    Lopez Zepeda, Lorena
    Noguez-Ramos, Alejandro
    Vazquez Juarez, Daniela
    Camacho Limas, Christian Patricio
    Regalado Porras, Gabriela Olivia
    Salcedo, Ivonne
    Rivera, Samuel
    Aguayo, Alvaro
    Blanco Vazquez, Yazmin Carolina
    Lopez Galindo, Angel Azael
    Shveid Gerson, Daniela
    Perez-Zincer, Fernando
    Alberto Serrano, Juan
    Fabian Martinez-Herrera, Jose
    Olivares, Guillermo
    Villalobos, Alberto
    Gonzalez De Leon, Cesar
    Gerson, Raquel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [25] Hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: Sequencing of chemotherapy and endocrine therapy
    Engel-Nitz, Nicole M.
    Hao, Yanni
    Rogerio, Jaqueline Willemann
    Turnbull, James D.
    Rey, Gabriel Gomez
    Sullivan, Jane
    Rossof, Arthur H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [26] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
    Chainitikun, Sudpreeda
    Long, James P.
    Rodriguez-Bautista, Ruben
    Iwase, Toshiaki
    Tripathy, Debu
    Fujii, Takeo
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (03) : 729 - 739
  • [27] Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)
    Signorovitch, James
    Wang, Jenny
    Tan, Ruo-Ding
    Thomason, Darren
    Kageleiry, Andrew
    Swallow, Elyse
    CANCER RESEARCH, 2015, 75
  • [28] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer
    Sudpreeda Chainitikun
    James P. Long
    Ruben Rodriguez-Bautista
    Toshiaki Iwase
    Debu Tripathy
    Takeo Fujii
    Naoto T. Ueno
    Breast Cancer Research and Treatment, 2020, 183 : 729 - 739
  • [29] REAL-WORLD HEMATOLOGIC AND LIVER FUNCTION-RELATED MONITORING PATTERNS IN FIRST-LINE THERAPY INITIATORS OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HUMAN-EPIDERMAL-GROWTH-FACTOR RECEPTOR-2 NEGATIVE (HR/HER2-) METASTATIC BREAST CANCER (MBC)
    Bauer, M.
    Tang, D.
    VALUE IN HEALTH, 2017, 20 (05) : A125 - A125
  • [30] Real-world experience of patients receiving treatment for hormone receptor-positive/human epidermal growth factor receptor-2 negative metastatic breast cancer: A global analysis of symptoms and side effects
    Rehnquist, Mk
    Partridge, Ann
    Lambert, Annabel
    Kurian, Allison
    Sadetsky, Natalia
    Freeman, Emily
    Carey, Lisa
    CANCER RESEARCH, 2024, 84 (09)
12345